Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.77 |
| ▸ | GSPT1 | P15170 | 4/20 | 0.77 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.77 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.62 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.51 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.51 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.47 |
| ▸ | SALL4 | Q9UJQ4 | 1/20 | 0.46 |
| ▸ | WIZ | O95785 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375227 | 1.00 | CRBN (0.77) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL17420610 | 0.94 | CRBN (0.74) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL29375675 | 0.94 | CRBN (0.74) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL29375241 | 0.92 | CRBN (0.73) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL17420545 | 0.92 | CRBN (0.73) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL17428565 | 0.92 | CRBN (0.65) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL17420690 | 0.91 | CRBN (0.81) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL29375777 | 0.91 | CRBN (0.81) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL17420614 | 0.91 | CRBN (0.73) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL29375787 | 0.91 | CRBN (0.73) | CRBNGSPT1DDB1CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | claimed |
| EP-3594211-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-10-25 | — | — | EP | claimed |
| CN-111170991-A | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2020-05-19 | — | — | CN | claimed |
| CN-106660991-B | Antiproliferative compounds and methods of use thereof | 细胞基因公司 | 2020-03-13 | — | — | CN | claimed |
| EP-3166937-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2019-09-04 | — | — | EP | claimed |
| US-20180221361-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2018-08-09 | — | — | US | claimed |
| US-9968596-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2018-05-15 | — | — | US | claimed |
| US-20180021325-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2018-01-25 | — | — | US | claimed |
| US-9808451-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2017-11-07 | — | — | US | claimed |
| US-20170007590-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2017-01-12 | — | — | US | claimed |
| US-9499514-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2016-11-22 | — | — | US | claimed |
| US-12474342-B2 | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies | CELGENE CORPORATION (US) | 2025-11-18 | — | — | US | disclosed |
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3594211-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3594211-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2016007848-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
| US-20160009683-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| WO-2016007848-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
| US-20160009683-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| US-20160009683-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12474342-B2 | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies | TSG101, BRCA1, TP53 | CRBN 3044/4885GSPT1 414/4885DDB1 172/4885 |
| US-20170007590-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | CRBN 1468/4885GSPT1 2184/4885DDB1 629/4885 |
| US-20160009683-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | CRBN 1468/4885GSPT1 2184/4885DDB1 629/4885 |
| US-20180021325-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | CRBN 1468/4885GSPT1 2184/4885DDB1 629/4885 |
| US-20180221361-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | CRBN 1468/4885GSPT1 2184/4885DDB1 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.